Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Fineline Cube Mar 10, 2026
Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Fineline Cube Mar 10, 2026
Company Drug

Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis

Fineline Cube Apr 23, 2023

Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...

Company Deals

Siemens Healthineers and China Chest Pain Center Launch Smart Training Program

Fineline Cube Apr 23, 2023

German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center...

Company Drug

Neurodawn Pharmaceutical’s Y-1 Receives NMPA Approval for Primary Intracranial Tumor Treatment

Fineline Cube Apr 23, 2023

Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has...

Company Deals

Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline

Fineline Cube Apr 23, 2023

Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic...

Company

Jiangsu Hengrui Pharmaceuticals Reports 2022 Revenue Dip and Increased R&D Investment

Fineline Cube Apr 23, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a China-based pharmaceutical company, has released its 2022 financial report,...

Company Drug

GenScript Biotech’s Subsidiary Legend Biotech Announces Positive CAR-T Therapy Results

Fineline Cube Apr 23, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Deals

HealZen Therapeutics and NeuShen Seal Deal for Global Rights to CNS Drug Programs

Fineline Cube Apr 21, 2023

China-based HealZen Therapeutics has entered into a licensing agreement with compatriot firm NeuShen, focusing on...

Drug R&D

AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research

Fineline Cube Apr 21, 2023

The 2023 edition of the American Association for Cancer Research (AACR) annual meeting has concluded,...

Company Deals

Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion

Fineline Cube Apr 21, 2023

China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round...

Company Deals

Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D

Fineline Cube Apr 21, 2023

China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580...

Company Deals

Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services

Fineline Cube Apr 21, 2023

China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million)...

Company Deals

Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform

Fineline Cube Apr 21, 2023

Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big...

Company Drug

Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China

Fineline Cube Apr 21, 2023

U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the...

Company Drug

BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer

Fineline Cube Apr 21, 2023

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the...

Company Deals

Zylox-Tonbridge Medical Teams Up with Hicicare Science for Guide Wire Product Sales in China

Fineline Cube Apr 21, 2023

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million

Fineline Cube Apr 21, 2023

Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s...

Company Drug

Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine

Fineline Cube Apr 21, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing...

Company Drug

Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC

Fineline Cube Apr 21, 2023

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III...

Company Deals

Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs

Fineline Cube Apr 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a...

Company Medical Device

Acotec Scientific’s Vericor-14 Microcatheter Receives NMPA Approval for Vascular Surgeries

Fineline Cube Apr 21, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Posts pagination

1 … 500 501 502 … 632

Recent updates

  • SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
  • Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
  • Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors
  • Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market
  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.